Crossject Equity 2024

Crossject Aktienanalyse

What does Crossject do?

Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Crossject's Equity

Crossject's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Crossject's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Crossject's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Crossject's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Crossject’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Crossject stock

What is the equity of Crossject this year?

Crossject has equity of 1.79 M EUR this year.

What was the equity of Crossject compared to the previous year?

The equity of Crossject has increased/decreased by -82.38% decreased compared to the previous year.

What impact does a high equity have on investors of Crossject?

A high equity is advantageous for investors of Crossject as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Crossject?

A low equity can be a risk for investors of Crossject, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Crossject affect the company?

An increase in equity of Crossject can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Crossject affect the company?

A reduction in equity of Crossject can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Crossject?

Some factors that can affect the equity of Crossject include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Crossject so important for investors?

The equity of Crossject is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Crossject take to change the equity?

To change equity, Crossject can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Crossject pay?

Over the past 12 months, Crossject paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crossject is expected to pay a dividend of 0 EUR.

What is the dividend yield of Crossject?

The current dividend yield of Crossject is .

When does Crossject pay dividends?

Crossject pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Crossject?

Crossject paid dividends every year for the past 0 years.

What is the dividend of Crossject?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Crossject located?

Crossject is assigned to the 'Health' sector.

Wann musste ich die Aktien von Crossject kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Crossject from 10/10/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Crossject pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Crossject in the year 2023?

In the year 2023, Crossject distributed 0 EUR as dividends.

In which currency does Crossject pay out the dividend?

The dividends of Crossject are distributed in EUR.